Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

BACKGROUND: Nanoparticle albumin-bound (nab)-paclitaxel has better efficacy, safety profiles, and no need to use prophylactic steroids compared with solvent-based paclitaxel. We performed a single arm, phase II study to evaluate the efficacy and safety of weekly nab-paclitaxel and gemcitabine combin...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Zhao, Yannan, Lv, Fangfang, Chen, She, Wang, Zhonghua, Zhang, Jian, Zhang, Sheng, Cao, Jun, Wang, Leiping, Cao, Enying, Wang, Biyun, Hu, Xichun
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6196471/
https://ncbi.nlm.nih.gov/pubmed/30348118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4936-y
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料